<p>Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - 獲取免費報告) 的股價在週二交易前跳漲。該股此前收於 18.33 美元，但開盤價為 19.39 美元。Kestra Medical Technologies 的股票最後交易價格為 19.0050 美元，成交量為 62,765 股。</p>
<h2>華爾街分析師觀點</h2>
<p>幾位研究分析師對該公司發佈了報告。BTIG Research 在 3 月 25 日的研究報告中重申了 “買入” 評級，並將 Kestra Medical Technologies 的目標價設定為 32.00 美元。Stifel Nicolaus 在 12 月 12 日的研究報告中將 Kestra Medical Technologies 的目標價設定為 30.00 美元。Piper Sandler 在 12 月 12 日的報告中將 Kestra Medical Technologies 的目標價從 27.00 美元上調至 30.00 美元，並給予該公司 “增持” 評級。Wells Fargo &amp; Company 在 12 月 12 日的研究報告中將 Kestra Medical Technologies 的目標價從 27.00 美元上調至 28.00 美元，並給予該公司 “增持” 評級。最後，摩根士丹利在 1 月 16 日的研究報告中將 Kestra Medical Technologies 的目標價設定為 24.00 美元。三位研究分析師給予該股 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “持有”，平均目標價為 28.80 美元。</p>
<p><strong>查看我們對 KMTS 的最新股票分析</strong></p>
<h2>Kestra Medical Technologies 股價上漲 3.2%</h2>
<p>該公司的債務與股本比率為 0.15，速動比率為 7.32，流動比率為 7.32。該公司的 50 日簡單移動平均線為 23.58 美元，200 日簡單移動平均線為 24.72 美元。該公司的市值為 11 億美元，市盈率為-4.75。</p>
<p>Kestra Medical Technologies (NASDAQ:KMTS - 獲取免費報告) 最近在 3 月 17 日宣佈了其季度財報。該公司報告季度每股收益為（0.61 美元），低於市場共識預期的（0.60 美元）0.01 美元。Kestra Medical Technologies 的淨利潤率為-171.87%，股本回報率為-65.49%。該公司季度收入為 2455 萬美元，季度收入同比增長 62.7%。</p>
<h2>Kestra Medical Technologies 內部活動</h2>
<p>在其他消息中，內部人士 Brian Daniel Webster 在 3 月 17 日的交易中出售了 15,000 股該公司的股票。股票以平均價格 20.27 美元出售，總價值為 304,050.00 美元。出售完成後，內部人士持有該公司 364,786 股股票，價值約為 7,394,212.22 美元。這代表其持股比例減少了 3.95%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接訪問。在過去三個月中，內部人士已出售價值 1,030,050 美元的 45,000 股公司股票。內部人士持有該公司 3.60% 的股份。</p>
<h2>對 Kestra Medical Technologies 的對沖基金觀點</h2>
<p>大型投資者最近買入和賣出了該公司的股票。Farther Finance Advisors LLC 在第四季度購買了 Kestra Medical Technologies 的新股份，價值 31,000 美元。Russell Investments Group Ltd.在第四季度將其在 Kestra Medical Technologies 的持股增加了 43.5%。Russell Investments Group Ltd.現在擁有 1,563 股該公司的股票，價值 41,000 美元，此前在此期間又購買了 474 股。China Universal Asset Management Co. Ltd.在第三季度購買了 Kestra Medical Technologies 的新股份，價值 48,000 美元。新澤西州警察和消防員退休系統在第二季度購買了 Kestra Medical Technologies 的新股份，價值 54,000 美元。最後，法國巴黎銀行金融市場在第三季度將其在 Kestra Medical Technologies 的持股增加了 148.9%。法國巴黎銀行金融市場現在擁有 2,738 股該公司的股票，價值 65,000 美元，此前在上個季度又購買了 1,638 股。</p>
<h2>Kestra Medical Technologies 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>我們是一家商業階段的可穿戴醫療設備和數字醫療公司，專注於通過直觀、智能和互聯的監測和治療干預技術來改善心血管疾病患者的結果。我們開發並商業化了我們的心臟恢復系統平台，這是一個綜合且先進的系統，將監測、治療、數字健康和患者支持服務整合為一個統一的解決方案。我們心臟恢復系統平台的基石是 ASSURE WCD，這是一種下一代可穿戴心臟復律除顫器（“WCD”），用於保護面臨突發心臟驟停（“SCA”）風險的患者，這是一項重大公共衞生問題，佔美國所有心血管死亡的約 50%。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Kestra Medical Technologies</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Kestra Medical Technologies 嗎？</h2>
<p>在你考慮投資 Kestra Medical Technologies 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Kestra Medical Technologies 並不在名單上。</p>
<p>雖然 Kestra Medical Technologies 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>在這裏查看五隻股票</p>

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

KMTS

<p>Kestra Medical Technologies（納斯達克代碼：KMTS）股價在開盤前從 18.33 美元跳漲至 19.39 美元，最終收於 19.0050 美元。分析師的評級各不相同，BTIG Research 維持 “買入” 評級，目標價為 32.00 美元。該公司報告的季度每股收益為（0.61 美元），未達到預期，但收入同比增長 62.7%。內部交易方面，Brian Daniel Webster 出售了 15,000 股。該公司專注於心血管疾病的可穿戴醫療設備，市值為 11 億美元，市盈率為-4.75</p>

<p>Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $18.33, but opened at $19.39. Kestra Medical Technologies shares last traded at $19.0050, with a volume of 62,765 shares traded.</p>
<div class="lb-trans"><p>Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - 獲取免費報告) 的股價在週二交易前跳漲。該股此前收於 18.33 美元，但開盤價為 19.39 美元。Kestra Medical Technologies 的股票最後交易價格為 19.0050 美元，成交量為 62,765 股。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several research analysts have issued reports on the company. BTIG Research restated a &#34;buy&#34; rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research report on Wednesday, March 25th. Stifel Nicolaus set a $30.00 price target on Kestra Medical Technologies in a research note on Friday, December 12th. Piper Sandler boosted their price objective on Kestra Medical Technologies from $27.00 to $30.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, December 12th. Wells Fargo &amp; Company upped their price objective on Kestra Medical Technologies from $27.00 to $28.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, December 12th. Finally, The Goldman Sachs Group set a $24.00 target price on Kestra Medical Technologies in a research note on Friday, January 16th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average target price of $28.80.</p>
<div class="lb-trans"><p>幾位研究分析師對該公司發佈了報告。BTIG Research 在 3 月 25 日的研究報告中重申了 “買入” 評級，並將 Kestra Medical Technologies 的目標價設定為 32.00 美元。Stifel Nicolaus 在 12 月 12 日的研究報告中將 Kestra Medical Technologies 的目標價設定為 30.00 美元。Piper Sandler 在 12 月 12 日的報告中將 Kestra Medical Technologies 的目標價從 27.00 美元上調至 30.00 美元，並給予該公司 “增持” 評級。Wells Fargo &amp; Company 在 12 月 12 日的研究報告中將 Kestra Medical Technologies 的目標價從 27.00 美元上調至 28.00 美元，並給予該公司 “增持” 評級。最後，摩根士丹利在 1 月 16 日的研究報告中將 Kestra Medical Technologies 的目標價設定為 24.00 美元。三位研究分析師給予該股 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “持有”，平均目標價為 28.80 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on KMTS</strong></p>
<div class="lb-trans"><p><strong>查看我們對 KMTS 的最新股票分析</strong></p>
</div><h2>Kestra Medical Technologies Stock Up 3.2%</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 股價上漲 3.2%</h2>
</div><p>The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. The company has a fifty day simple moving average of $23.58 and a two-hundred day simple moving average of $24.72. The firm has a market capitalization of $1.10 billion and a PE ratio of -4.75.</p>
<div class="lb-trans"><p>該公司的債務與股本比率為 0.15，速動比率為 7.32，流動比率為 7.32。該公司的 50 日簡單移動平均線為 23.58 美元，200 日簡單移動平均線為 24.72 美元。該公司的市值為 11 億美元，市盈率為-4.75。</p>
</div><p>Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The firm had revenue of $24.55 million for the quarter. The business's revenue for the quarter was up 62.7% on a year-over-year basis.</p>
<div class="lb-trans"><p>Kestra Medical Technologies (NASDAQ:KMTS - 獲取免費報告) 最近在 3 月 17 日宣佈了其季度財報。該公司報告季度每股收益為（0.61 美元），低於市場共識預期的（0.60 美元）0.01 美元。Kestra Medical Technologies 的淨利潤率為-171.87%，股本回報率為-65.49%。該公司季度收入為 2455 萬美元，季度收入同比增長 62.7%。</p>
</div><h2>Insider Activity at Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 內部活動</h2>
</div><p>In other news, insider Brian Daniel Webster sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $20.27, for a total value of $304,050.00. Following the completion of the sale, the insider owned 364,786 shares of the company's stock, valued at approximately $7,394,212.22. This represents a 3.95% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 45,000 shares of company stock valued at $1,030,050. Insiders own 3.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，內部人士 Brian Daniel Webster 在 3 月 17 日的交易中出售了 15,000 股該公司的股票。股票以平均價格 20.27 美元出售，總價值為 304,050.00 美元。出售完成後，內部人士持有該公司 364,786 股股票，價值約為 7,394,212.22 美元。這代表其持股比例減少了 3.95%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接訪問。在過去三個月中，內部人士已出售價值 1,030,050 美元的 45,000 股公司股票。內部人士持有該公司 3.60% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>對 Kestra Medical Technologies 的對沖基金觀點</h2>
</div><p>Large investors have recently bought and sold shares of the business. Farther Finance Advisors LLC purchased a new stake in Kestra Medical Technologies during the fourth quarter worth $31,000. Russell Investments Group Ltd. increased its holdings in shares of Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock valued at $41,000 after acquiring an additional 474 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Kestra Medical Technologies in the 3rd quarter worth $48,000. Police &amp; Firemen s Retirement System of New Jersey bought a new position in shares of Kestra Medical Technologies in the 2nd quarter worth $54,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock worth $65,000 after purchasing an additional 1,638 shares during the last quarter.</p>
<div class="lb-trans"><p>大型投資者最近買入和賣出了該公司的股票。Farther Finance Advisors LLC 在第四季度購買了 Kestra Medical Technologies 的新股份，價值 31,000 美元。Russell Investments Group Ltd.在第四季度將其在 Kestra Medical Technologies 的持股增加了 43.5%。Russell Investments Group Ltd.現在擁有 1,563 股該公司的股票，價值 41,000 美元，此前在此期間又購買了 474 股。China Universal Asset Management Co. Ltd.在第三季度購買了 Kestra Medical Technologies 的新股份，價值 48,000 美元。新澤西州警察和消防員退休系統在第二季度購買了 Kestra Medical Technologies 的新股份，價值 54,000 美元。最後，法國巴黎銀行金融市場在第三季度將其在 Kestra Medical Technologies 的持股增加了 148.9%。法國巴黎銀行金融市場現在擁有 2,738 股該公司的股票，價值 65,000 美元，此前在上個季度又購買了 1,638 股。</p>
</div><h2>Kestra Medical Technologies Company Profile</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.</p>
<div class="lb-trans"><p>我們是一家商業階段的可穿戴醫療設備和數字醫療公司，專注於通過直觀、智能和互聯的監測和治療干預技術來改善心血管疾病患者的結果。我們開發並商業化了我們的心臟恢復系統平台，這是一個綜合且先進的系統，將監測、治療、數字健康和患者支持服務整合為一個統一的解決方案。我們心臟恢復系統平台的基石是 ASSURE WCD，這是一種下一代可穿戴心臟復律除顫器（“WCD”），用於保護面臨突發心臟驟停（“SCA”）風險的患者，這是一項重大公共衞生問題，佔美國所有心血管死亡的約 50%。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Kestra Medical Technologies</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Kestra Medical Technologies</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kestra Medical Technologies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Kestra Medical Technologies 嗎？</h2>
</div><p>Before you consider Kestra Medical Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Kestra Medical Technologies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Kestra Medical Technologies 並不在名單上。</p>
</div><p>While Kestra Medical Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kestra Medical Technologies 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看五隻股票</p>
</div>

Kestra Medical Technologies (NASDAQ:KMTS) 股價跳空高開 - 是否仍然值得買入？